It had also been showed that treatment with 3P10, a therapeutic antagonistic monoclonal antibody that targets GFRAL and inhibits RET signaling by preventing the GDF15-driven interaction of RET with GFRAL on the cell surface, reverses excessive lipid oxidation in tumor-bearing mice and prevents cancer cachexia, even under calorie-restricted conditions [29]. The gene discussed is GFRAL; the disease is neoplasm.